TRACON Pharmaceuticals Inc
OTC:TCON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bawan Company SJSC
SAU:1302
|
SA |
|
A
|
Alphabet Inc
XETRA:ABEA
|
US |
|
Ride On Express Holdings Co Ltd
TSE:6082
|
JP |
|
WiseTech Global Ltd
ASX:WTC
|
AU |
|
OS Co Ltd
TSE:9637
|
JP |
|
JSR Corp
TSE:4185
|
JP |
|
Zhejiang Lante Optics Co Ltd
SSE:688127
|
CN |
|
AGM Group Holdings Inc
NASDAQ:AGMH
|
HK |
|
S
|
Solowin Holdings Ltd
NASDAQ:SWIN
|
HK |
|
Tecnisa SA
BOVESPA:TCSA3
|
BR |
|
Maan Aluminium Ltd
NSE:MAANALU
|
IN |
TRACON Pharmaceuticals Inc
Other Items
TRACON Pharmaceuticals Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TRACON Pharmaceuticals Inc
OTC:TCON
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
TRACON Pharmaceuticals Inc
Glance View
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 19 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The firm's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.
